retatrutide 2.5 mg 🎙️ NEW EPISODE: Retatrutide—The Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in Retatrutide used for the treatment
Description
Still meaningful results with proper timing
Metformin is also associated with modest weight loss or weight neutrality, making it suitable for long-term use
GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: novel therapeutic agents for metabolic dysfunction-associated steatohepatitis
In fact, as many as 50% of people prescribed these weight loss meds may quit within a year due to side effects
The clinical work doesn't wait for the literature to fully resolve
Never discontinue or adjust your semaglutide dose without consulting your healthcare provider, as abrupt changes may affect glycemic control in diabetes management or weight management progress
